Scinai Immunotherapeutics shares surge 11.38% after-hours as investors anticipate AGM vote on below-industry-average CEO compensation.

Scinai Immunotherapeutics Ltd. surged 11.38% in after-hours trading following the announcement of its Annual General Meeting on December 22nd and details of CEO Amir Reichman’s compensation. The CEO’s total pay of $659,000, a 29% decrease from 2023 and 47% below the industry median, was highlighted as a potential positive for shareholders, despite a 97% three-year shareholder loss. The lower-than-industry compensation, combined with 85% EPS growth over three years, may have signaled cost discipline and growth potential, prompting investor optimism. The upcoming AGM, where shareholders can influence executive remuneration, likely added to the stock’s post-market rally as investors anticipated governance improvements.